Multiple

Saniona publishes its year-end report for 2021

Retrieved on: 
Thursday, February 24, 2022
Ownership, Prader–Willi syndrome, Achievement, Board, Regulation of tobacco by the U.S. Food and Drug Administration, Multiple, SEK, Novartis, Therapy, PWS, US, Acquisition, Food, Director, Degenerative disease, HO, FDA, Patient, Chemistry, CEO, Animal, Pharmaceutical industry

Saniona initiated a Phase 2b clinical trial of Tesomet in patients with hypothalamic obesity (HO); data are expected in the second half of 2023.

Key Points: 
  • Saniona initiated a Phase 2b clinical trial of Tesomet in patients with hypothalamic obesity (HO); data are expected in the second half of 2023.
  • Saniona completed the submission of all information previously requested by the U.S. Food and Drug Administration (FDA) regarding its chemistry, manufacturing and controls program for Tesomet capsules.
  • Saniona initiated the Multiple Ascending Dose stage of its Phase 1 trial of SAN711; data are expected by the end of the first half of 2022.
  • Saniona received SEK 7.3 million (US$0.8 million) from Novartis related to Novartiss January 2021 acquisition of Cadent Therapeutics, in which Saniona held a 3% ownership stake.

New MAVENCLAD® Data at ACTRIMS Forum 2022 Show Favourable Efficacy Outcomes Versus Other Oral DMTs and Lower Occurrence of Further Relapses or Disability Progression

Retrieved on: 
Thursday, February 24, 2022
Technology, Other Technology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Data Management, Other Science, Science, Risk, DMF, ORACLE, Entrepreneurship, Intelligence, Interferon beta-1a, Royal commission, Hypoesthesia, Lupus, Generalization (learning), Electronics, Incidence, Department, DMT, MBBS, Monash University, Â, Research, Lymphocytopenia, Safety, Disease, Dimethyl fumarate, Multiple sclerosis, Treatment, MS, Doctor of Philosophy, ARR, Interferon, RRMS, Merck Millipore, European Commission, Health, SLE, AE, CLARITY, Great America Committee, Patient, Merck Serono, Union, CDMS, DMTS, Neuro, Central nervous system, Lists of diseases, Disability, Phase, Cladribine, Lymphocyte, Clinical trial, Tablet, RMS, EC, Adult, Science, Neurology, Infection, Pharmaceutical industry, EU, Merck, FRACP, Multiple

These data will be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022, taking place 24-26 February 2022.

Key Points: 
  • These data will be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022, taking place 24-26 February 2022.
  • Time-to-first relapse in MAVENCLAD-treated patients was 40%, 42% and 67% lower than in patients treated with fingolimod, DMF and teriflunomide, respectively.
  • The time to switch rate in patients treated with MAVENCLAD was 4, 7 and 6.5 times lower than fingolimod, DMF and teriflunomide, respectively.
  • This information showed us that in GLIMPSE, MAVENCLAD had better relapse outcomes and longer treatment persistence compared to other oral DMTs, including fingolimod.

Innovation leader Jeroen Tas Joins Quantiphi's Board of Directors

Retrieved on: 
Thursday, January 27, 2022
Gaia, Cloud, Philips, Delhivery, Industry, Ernst & Young Entrepreneur of the Year Award, IEX, Corporation, AI, Machine learning, AISBL, Director, Association, Free University, Board, Mphasis, Multiple, Citigroup, Ecosystem, Computer science, Heart, CEO, Congress, Technology, Year, Anomaly, De World International Secondary School, Leadership

MARLBOROUGH, Mass., Jan. 27, 2022 /PRNewswire-PRWeb/ --Quantiphi, an AI-first digital engineering company, announced today that it is delighted to have Jeroen Tas join Quantiphi's Board of Directors.

Key Points: 
  • MARLBOROUGH, Mass., Jan. 27, 2022 /PRNewswire-PRWeb/ --Quantiphi, an AI-first digital engineering company, announced today that it is delighted to have Jeroen Tas join Quantiphi's Board of Directors.
  • "Jeroen is a visionary with an exceptional track record and we are elated to welcome him to Quantiphi," said Asif Hasan, Co-founder, Quantiphi.
  • "A seasoned innovator with valuable industry experience and insight into the technology world, Jeroen brings an entrepreneurial spirit and unmatched enthusiasm to the Quantiphi Board.
  • Jeroen currently is a member of the Board of Directors of Gaia-X Association for Data and Cloud (AISBL).

BC Home Sales Could Drop 25 Per Cent After Bank of Canada Rate Tightening

Retrieved on: 
Tuesday, January 18, 2022
British Columbia Real Estate Association, Bank of Canada, Bank, Columbia, GLOBE, Â, Multiple, Policy, Property management, Real estate, BC

The Impact of Bank of Canada Tightening on BC Housing Markets , was written by the associations Chief Economist Brendon Ogmundson and explores both the historical impacts of the Bank raising its policy rate and a number of scenarios likely to play out in BCs housing market as a result.

Key Points: 
  • The Impact of Bank of Canada Tightening on BC Housing Markets , was written by the associations Chief Economist Brendon Ogmundson and explores both the historical impacts of the Bank raising its policy rate and a number of scenarios likely to play out in BCs housing market as a result.
  • In the past, Bank of Canada tightening has usually led to falling home sales and flattening home prices, so it wouldnt be a surprise to see the same happening in the upcoming round of tightening says Ogmundson.
  • The Bank of Canada has signaled that in response to elevated Canadian inflation, it will begin raising its policy rate or tightening monetary policy this year.
  • Our model simulations show only a minor impact on home prices in the first two years following the Bank raising its overnight rate.

129BC Announces Reverse Takeover Transaction with ClearIT

Retrieved on: 
Thursday, December 9, 2021
Dermatology, Company, Agreement, Multiple, Seed, Transaction, News, Nomination, 129BC, The Exchange, Person, Patent, Good, Compliance, Disclosure, Cryptocurrency, Security (finance)

Ltd. ("129BC" or the "Company") announces that it has entered into a binding agreement (the "Agreement") dated December 6, 2021, with Clear Intradermal Technologies, Inc. ("ClearIT") to complete a business combination by way of a transaction that will constitute a reverse takeover of the Company by ClearIT (the "Transaction").

Key Points: 
  • Ltd. ("129BC" or the "Company") announces that it has entered into a binding agreement (the "Agreement") dated December 6, 2021, with Clear Intradermal Technologies, Inc. ("ClearIT") to complete a business combination by way of a transaction that will constitute a reverse takeover of the Company by ClearIT (the "Transaction").
  • The Transaction will be structured as an amalgamation, arrangement, takeover bid, share purchase or other similar form of transaction or a series of transactions that have a similar effect with the Company acquiring all of the shares of common stock in the capital of ClearIT ("ClearIT Shares").
  • The resulting issuer that will exist upon completion of the Transaction (the "Resulting Issuer") will change its business to the current business of ClearIT.
  • Further details about the proposed Transaction, the ClearIT Financings and the Resulting Issuer will be provided in the disclosure document to be prepared and filed in connection with the Transaction.

The 27th annual REALTORS Care® Blanket Drive extended to support BC’s disaster relief efforts

Retrieved on: 
Monday, November 22, 2021
Landslide, Government, Red, Partnership, Multiple, Flood, Ottawa Real Estate Board, Fraser Valley, Drive, GLOBE, Organization, Board, Organic, International Red Cross and Red Crescent Movement, Statistics, Property management

To help, the Real Estate Board of Greater Vancouver and the Fraser Valley Real Estate Board will direct all financial donations raised during this years REALTORS Care Blanket Drive to support the people affected by this natural disaster.

Key Points: 
  • To help, the Real Estate Board of Greater Vancouver and the Fraser Valley Real Estate Board will direct all financial donations raised during this years REALTORS Care Blanket Drive to support the people affected by this natural disaster.
  • "That's why we decided to pivot this years campaign to support the Red Cross in its province-wide relief efforts."
  • All REALTORS Care Blanket Drive fundraising proceeds will go to the Canadian Red Crosss British Columbia Floods and Extreme Weather Appeal.
  • The REALTORS Care Blanket Drive is a partnership between the REALTORS of the Fraser Valley, Greater Vancouver, and Chilliwack and District Real Estate Boards and their communities.

Martin Moradian, DPM, FABMSP, AACFAS is recognized by Continental Who's Who

Retrieved on: 
Monday, November 15, 2021
University, View, Podiatrist, Associate, Mentorship, PRP, Wart, Partner, American Podiatric Medical Association, Multiple, Continental, Ankle, CA, Multimedia, Injection, Program, American Board of Commissioners for Foreign Missions, Pain, City, Medicine, Private practice, Injury, Diabetes, Conditional sentence, Patient, American College, DPM

Martin Moradian, DPM, FABMSP, AACFAS is a Partner and Podiatrist at MB Comprehensive Foot and Ankle Specialists, his private practice in Glendale, CA.

Key Points: 
  • Martin Moradian, DPM, FABMSP, AACFAS is a Partner and Podiatrist at MB Comprehensive Foot and Ankle Specialists, his private practice in Glendale, CA.
  • He then attended the California College of Podiatric Medicine in San Francisco, graduating with his Doctor of Podiatric Medicine degree in 2002.
  • He excelled in the program, and was given the title of Chief Resident of the Baja Project for Crippled Children.
  • He would like to dedicate this honorable recognition to his mentors and residency directors, Alan Snyder, DPM, and Carl Wareich, DPM.

The 27th annual REALTORS Care® Blanket Drive begins November 15

Retrieved on: 
Tuesday, November 9, 2021
Lower, Toronto Regional Real Estate Board, Volunteering, Drive, Organization, Greater Vancouver, Multiple, Organic, COVID-19, Social media, Partnership, GLOBE, Collection, Board, Statistics, Animal, Property management

The REALTORS Care Blanket Drive will combine its traditional collection and distribution of warm clothes and blankets with an online fundraiser for our partner charities due to lighter restrictions of the COVID-19 pandemic.

Key Points: 
  • The REALTORS Care Blanket Drive will combine its traditional collection and distribution of warm clothes and blankets with an online fundraiser for our partner charities due to lighter restrictions of the COVID-19 pandemic.
  • The 27-year-old blanket drive campaign is a partnership among the Lower Mainlands three real estate boards, the Real Estate Board of Greater Vancouver (REBGV), the Fraser Valley Real Estate Board (FVREB), and the Chilliwack and District Real Estate Board (CADREB).
  • With the success of our online fundraiser last year, were holding both a blanket drive and financial drive in 2021 to help meet these dual needs of the charities.
  • Help spread the word about the REALTORS Care Blanket Charity Drive!

The Metals Company Conducts Ground-Breaking Deepwater Sampling Campaign in Eastern Pacific on Path to Meet Global Demand for Critical Minerals

Retrieved on: 
Monday, November 8, 2021
Manufacturing, Professional Services, Mining, Minerals, Maritime, Transport, Natural Resources, Research, Environment, Engineering, Science, Finance, Nickel, University, Data, Mineral, CCZ, International Seabed Authority, Metal, Copper, Private Securities Litigation Reform Act, Clipperton Fracture Zone, American Metal Company, Accident, TMC, Prospectus, NASDAQ, Knowledge, Salinity, Multiple, CEO, Transport, COVID, COVID-19, Multimedia, Research, MOCNESS, Biodiversity, Biophysical environment, Kingdom, Forward-looking statement, Animal, Regulation, Manganese, University of Hawaiʻi, EV, Cobalt, Oxygen, ESG, SEC, Collection, Temperature, Time, Pacific Ocean, Glacier Media, Exploration, Environmental policy of the Joe Biden administration, Republic, Rare-earth element

Researchers on board achieved a world-first by conducting the deepest pelagic biota sampling at depths down to 4,000 meters in the Eastern Tropical Pacific.

Key Points: 
  • Researchers on board achieved a world-first by conducting the deepest pelagic biota sampling at depths down to 4,000 meters in the Eastern Tropical Pacific.
  • These latest insights build upon the baseline dataset collected on the Companys NORI-D block, sponsored by the Republic of Nauru.
  • In the U.S., the Biden Administration recently elevated nickel to critical status singling it out as one of three battery metals deemed most critical to US interests.
  • TMC cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made.

Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers

Retrieved on: 
Wednesday, October 27, 2021
Safety, Science, SAD, MAD, MD, Biotechnology, Entrepreneurship, LinkedIn, Toll-like receptor, Drug development, Boston Business Journal, TLR, Twitter, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, Investor, Lymphatic system, Boston, Receptor (biochemistry), Risk, Sanofi, Conference, International, Atopic dermatitis, Adult, PK, Multiple, Clinical trial, Webcast, CEO, COVID-19, Inflammation, Conference call, MidOcean Partners, Hidradenitis suppurativa, Pharmacokinetics, Nasdaq, Therapy, Rheumatoid arthritis, Doctor of Philosophy, STAT3, Plasma, Pharmaceutical industry, Fine chemical

WATERTOWN, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented new safety, pharmacokinetic (PK) and pharmacodynamic (PD) data, including cytokines, from the Single Ascending Dose (SAD) portion of the KT-474 Phase 1 randomized, placebo-controlled healthy volunteer trial, at the 4th Annual Targeted Protein Degradation Summit.

Key Points: 
  • In July 2021, Kymera initiated dosing of healthy volunteers in the Multiple Ascending Dose (MAD) portion of the Phase 1 trial of KT-474.
  • The multiple ascending dose portion of the trial is designed to evaluate repeat daily dosing of KT-474 for 14 days, beginning with the 25 mg dose, in healthy volunteers randomized 9:3 to KT-474 or placebo.
  • Kymera plans to present data from the MAD portion of the healthy volunteer study before year end.
  • IRAK4 is a key protein involved in inflammation mediated by the activation of toll-like receptors (TLRs) and IL-1 receptors (IL-1Rs).